Cargando…

Orthogonal modular biosynthesis of nanoscale conjugate vaccines for vaccination against infection

Conjugate vaccines represent one of the most effective means for controlling the occurrence of bacterial diseases. Although nanotechnology has been greatly applied in the field of vaccines, it is seldom used for conjugate vaccine research because it is very difficult to connect polysaccharides and n...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin, Pan, Chao, Sun, Peng, Peng, Zhehui, Feng, Erling, Wu, Jun, Wang, Hengliang, Zhu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tsinghua University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359766/
https://www.ncbi.nlm.nih.gov/pubmed/34405037
http://dx.doi.org/10.1007/s12274-021-3713-4
Descripción
Sumario:Conjugate vaccines represent one of the most effective means for controlling the occurrence of bacterial diseases. Although nanotechnology has been greatly applied in the field of vaccines, it is seldom used for conjugate vaccine research because it is very difficult to connect polysaccharides and nanocarriers. In this work, an orthogonal and modular biosynthesis method was used to produce nanoconjugate vaccines using the SpyTag/SpyCatcher system. When SpyTag/SpyCatcher system is combined with protein glycosylation technology, bacterial O-polysaccharide obtained from Shigela flexneri 2a can be conjugated onto the surfaces of different virus-like particles (VLPs) in a biocompatible and controlled manner. After confirming the excellent lymph node targeting and humoral immune activation abilities, these nanoconjugate vaccines further induced efficient prophylactic effects against infection in a mouse model. These results demonstrated that natural polysaccharide antigens can be easily connected to VLPs to prepare highly efficient nanoconjugate vaccines. To the best of the researchers’ knowledge, this is the first time VLP-based nanoconjugate vaccines are produced efficiently, and this strategy could be applied to develop various pathogenic nanoconjugate vaccines. [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material (Figs. S1–S9) is available in the online version of this article at 10.1007/s12274-021-3713-4.